Omeros Corp., of Seattle, reported Phase II and III data showing OMS302 reduces the incidence of miosis during intraocular lens replacement by 2.5 mm or more and reduces the incidence of the pupil constricting to less than 6 mm in diameter throughout surgery

Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like peptide 1 receptor agonist, to insulin glargine, as measured by the reduction of hemoglobin A1c levels, were met in two studies, AWARD-2 and AWARD-4

Sangamo BioSciences Inc., of Richmond, Calif., reported Phase I data showing that SB-728-T treatment in HIV-infected subjects led to durable reconstitution of the immune system driven by increases in total CD4-positive central memory T cells (Tcms) and CCR5-protected Tcms

usual care in patients with noncancer-related pain and opioid-induced constipation, with data showing that the most commonly reported adverse events occurring more frequently in the naloxegol arm included abdominal pain, diarrhea, nausea and headache

CoDa Therapeutics Inc., of San Diego, reported Phase IIb data showing that Nexagon in patients with chronic venous leg ulcers was found to be safe and produced an increase in complete healing in the vehicle-controlled trial

Proteon Therapeutics Inc., of Waltham, Mass., reported Phase II data showing that treatment with PRT-201 in chronic kidney disease patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis prolonged unassisted patency and improved the rate of AFV maturation

Inovio Pharmaceuticals Inc., of Blue Bell, Pa., reported interim Phase I data showing that a single dose of its H1N1 universal SynCon flu vaccine followed with a dose of a seasonal flu vaccine generated protective immune responses in 40 percent of trial subjects, compared with a 20 percent response rate in elderly patients who received the seasonal flu vaccine alone

Upsher-Smith Laboratories Inc., of San Diego, said Phase I data showing that USL261 (intranasal midazolam) demonstrated that maximum midazolam plasma concentrations were rapidly achieved after dosing, and both midazolam and its metabolite were rapidly eliminated

PaxVax Inc., of Menlo Park, Calif., reported Phase I data showing that its single-dose oral cholera vaccine candidate, PXVX0200, was highly immunogenic and that seroconversion to vibriocidal antibody occurred in 89 percent of vaccinated subjects by day 14

Celldex Therapeutics Inc., of Needham, Mass., reported Phase I data showing positive effects of CDX-1401 in solid tumors when given in combination with Toll-like receptor agonist resiquimod and/or Poly ICLC (Hiltonol

Nabi Biopharmaceuticals Inc., of Rockville, Md., reported Phase II data showing that smoking cessation candidate NicVAX (nicotine conjugate immunotherapeutic) in combination with Chantix (varenicline, Pfizer Inc.) did not meet the study's primary endpoint

Cancer Research UK, of London, reported Phase III data showing that elderly patients with advanced non-small-cell lung cancer who developed a rash within 28 days of receiving targeted therapy Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.) survived an average of 6.2 months, compared to 4.1 months for patients who received placebo

Actinium Pharmaceuticals Inc., of New York, presented Phase I data showing that Actimab-A, its antibody-directed alpha-emitter drug candidate for front-line acute myeloid leukemia (AML) in older patients, demonstrated significant antileukemic activity across all dose levels

Pierre Fabre Dermatolgie Laboratories, of Castres, France, a subsidiary of Pierre Fabre Laboratories, reported Phase III data showing that propranolol oral solution in infantile hemangioma resulted in complete or nearly complete resolution of the hemangioma for a sizeable majority of the infants who were treated, compared to an almost complete lack of effect from placebo

Cempra Inc., of Chapel Hill, N.C., disclosed positive top-line data showing that solithromycin cleared infections in patients with uncomplicated urogenital gonorrhea

Intarcia Therapeutics Inc., of Hayward, Calif., reported an analysis of Phase II data showing that two doses of ITCA 650, a continuous subcutaneous delivery of exenatide, in patients with Type II diabetes produced a 1 percent mean reduction in HbA1c at week 12, compared to a 0.7 percent reduction for patients receiving twice-daily Byetta (exenatide, Amylin Pharmaceuticals Inc.), though a lower incidence of nausea over time was seen in the 20 mcg/day dose of ITCA 650 vs

Diartis Pharmaceuticals Inc., of Mountain View, Calif., reported Phase I data showing that Type II diabetes candidate VRS-859 (exenatide-XTEN), a long-acting glucagon-like peptide-1 analogue, was well tolerated in repeated dosings of 200 mg per month...Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said Phase I data showing that two potential therapies targeting ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies, were

Circassia Ltd., of Oxford, UK, reported Phase II data showing that patients who received four doses of its its ToleroMune cat allergy treatment over 12 weeks maintained a significantly greater improvement in symptoms one year after the start of the study, compared to those in the placebo group (p = 0.0104

Vertex Pharmaceuticals Inc., of Cambridge, Mass., and collaborator Alios BioPharma Inc., of South San Francisco, reported results from a viral kinetic study of adenosine nucleotide analogue prodrug ALS-2158 in hepatitis C, with data showing that seven days of dosing with up to 900 mg of the drug was well tolerated in people with genotype 1 chronic hepatitis C virus (HCV), but there was insufficient antiviral activity to warrant proceeding with further clinical development